Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study

Javier Mar (), Oliver Ibarrondo, Carlo Delfin S. Estadilla, Nico Stollenwerk, Fernando Antoñanzas, Rubén Blasco-Aguado, Igor Larrañaga, Joseba Bidaurrazaga and Maíra Aguiar
Additional contact information
Javier Mar: Osakidetza Basque Health Service, Debagoiena Integrated Health Organization
Oliver Ibarrondo: Osakidetza Basque Health Service, Debagoiena Integrated Health Organization
Carlo Delfin S. Estadilla: Basque Center for Applied Mathematics
Nico Stollenwerk: Basque Center for Applied Mathematics
Fernando Antoñanzas: Universidad de La Rioja
Rubén Blasco-Aguado: Basque Center for Applied Mathematics
Igor Larrañaga: Osakidetza Basque Health Service, Debagoiena Integrated Health Organization
Joseba Bidaurrazaga: Basque Government Health Department
Maíra Aguiar: Basque Center for Applied Mathematics

PharmacoEconomics, 2024, vol. 42, issue 2, No 7, 219-229

Abstract: Abstract Background and Objective Coronavirus disease 2019 (COVID-19) vaccines are extremely effective in preventing severe disease, but their real-world cost effectiveness is still an open question. We present an analysis of the cost-effectiveness and economic impact of the initial phase of the COVID-19 vaccination rollout in the Basque Country, Spain. Methods To calculate costs and quality-adjusted life years for the entire population of the Basque Country, dynamic modelling and a real-world data analysis were combined. Data on COVID-19 infection outcomes (cases, hospitalisations, intensive care unit admissions and deaths) and population characteristics (age, sex, socioeconomic status and comorbidity) during the initial phase of the vaccination rollout, from January to June of 2021, were retrieved from the Basque Health Service database. The outcomes in the alternative scenario (without vaccination) were estimated with the dynamic model used to guide public health authority policies, from February to December 2020. Individual comorbidity-adjusted life expectancy and costs were estimated. Results By averting severe disease-related outcomes, COVID-19 vaccination resulted in monetary savings of €26.44 million for the first semester of 2021. The incremental cost-effectiveness ratio was €707/quality-adjusted life year considering official vaccine prices and dominant real prices. While the analysis by comorbidity showed that vaccines were considerably more cost effective in individuals with pre-existing health conditions, this benefit was lower in the low socioeconomic status group. Conclusions The incremental cost-effectiveness ratio of the vaccination programme justified the policy of prioritising high-comorbidity patients. The initial phase of COVID-19 vaccination was dominant from the perspective of the healthcare payer.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-023-01326-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:42:y:2024:i:2:d:10.1007_s40273-023-01326-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-023-01326-y

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().